OTCM
MKGAF
Market cap71bUSD
, Last price
Name
Merck KGaA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Globally, MERCK Kommanditgesellschaft auf Aktien conducts operations across the healthcare, life science, and electronics sectors. The company is actively involved in the research, development, production, and commercialization of both pharmaceutical and biological prescription medications. These treatments target a range of medical conditions, including those in neurology, immunology, oncology, fertility, and cardiometabolic and endocrine disorders. Furthermore, its life science division furnishes essential products, instruments, and services to support research facilities, pharmaceutical and biotechnology manufacturing, and industrial as well as analytical testing laboratories. Within its electronics segment, MERCK supplies crucial materials for integrated circuits, liquid crystals, organic light-emitting diodes (OLEDs), photoresists, smart antenna systems, and liquid crystal glazing solutions. It also produces specialized effect pigments extensively utilized in applications such as automotive coatings, cosmetics, and various industrial and plastics manufacturing. MERCK maintains strategic partnerships with Pfizer Inc., has an agreement with Novartis AG, and holds license arrangements with Debiopharm International SA and MoonLake Immunotherapeutics AG. Established in 1668, the firm's headquarters are located in Darmstadt, Germany, and it operates as a subsidiary of E. Merck Kommanditgesellschaft.
Related entities
Parent
E. Merck KG
Subsidiaries (56)
ARES TRADING SA
AZ Electronic Materials (Luxembourg) S.à r.l.
BIORELIANCE LTD.
EMD Finance LLC
EMD Millipore Corporation
Lamberts Healthcare Limited
meokeu-illegteulonigmeotilieoljeu jusighoesa
Merck & Cie KmG
Merck (Schweiz) AG
Merck 13. Allgemeine Beteiligungs-GmbH
Merck Aktiebolag
Merck B.V.
Merck Biopharma Distribution S.A. de C.V.
Merck Business Solutions Asia Inc.
MERCK CAPITAL LIMITED
Merck Electronics KGaA
Merck Export GmbH
Merck Financial Services GmbH
Merck Financial Trading GmbH
MERCK FINANZ S.à r.l.
Key people
Belen Garijo
Chairman of the Executive Board, Chief Executive Officer · since 2021
Sascha Held
Vice Chairman of the Supervisory Board · since 2020
Chief Financial Officer, Member of the Executive Board · since 2023
Khadija Hammada
Chief People Officer · since 2025
Florian Schraeder
Head of Investor Relations · since 2024
Danny Bar-zohar
Member of the Executive Board, Chief Executive Officer - Pharmaceuticals Division
Kai Beckmann
Member of the Executive Board, Chief Executive Officer - Electronics · since 2021
Jean-charles Wirth
Member of the Executive Board, Chief Executive Officer - the Life Science unit · since 2025
Michael Kleinemeier
Independent Chairman of the Supervisory Board · since 2024
Barbara Lambert
Independent Member of the Supervisory Board · since 2023
Independent Member of the Supervisory Board · since 2024
Independent Member of the Supervisory Board · since 2024
Daniel Thelen
Independent Member of the Supervisory Board · since 2019
Katja Vila
Independent Member of the Supervisory Board · since 2024
Member of the Supervisory Board · since 2022
Carla Kriwet
Independent Member of the Supervisory Board · since 2024
Anne Lange
Member of the Supervisory Board, Employee Representative · since 2019
Dietmar Oeter
Member of the Supervisory Board · since 2020
Alexander Putz
Member of the Supervisory Board, Employee Representative · since 2020
Christian Raabe
Member of the Supervisory Board · since 2019
Headquarters & legal address
Frankfurter Straße 250
Darmstadt, HE 64293
DE
Darmstadt, HE 64293
DE
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||